262 related articles for article (PubMed ID: 31075399)
1. The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation.
Zhang M; Wang B; Urabe G; Huang Y; Plutzky J; Kent KC; Guo LW
Cell Signal; 2019 Sep; 61():20-29. PubMed ID: 31075399
[TBL] [Abstract][Full Text] [Related]
2. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
[TBL] [Abstract][Full Text] [Related]
3. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
5. Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution.
Vollmuth F; Blankenfeldt W; Geyer M
J Biol Chem; 2009 Dec; 284(52):36547-36556. PubMed ID: 19828451
[TBL] [Abstract][Full Text] [Related]
6. miRNA-200c-3p promotes endothelial to mesenchymal transition and neointimal hyperplasia in artery bypass grafts.
Chen D; Zhang C; Chen J; Yang M; Afzal TA; An W; Maguire EM; He S; Luo J; Wang X; Zhao Y; Wu Q; Xiao Q
J Pathol; 2021 Feb; 253(2):209-224. PubMed ID: 33125708
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.
Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X
Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780
[TBL] [Abstract][Full Text] [Related]
8. The binding mechanism of NHWD-870 to bromodomain-containing protein 4 based on molecular dynamics simulations and free energy calculation.
Shi M; He J; Weng T; Shi N; Qi W; Guo Y; Chen T; Chen L; Xu D
Phys Chem Chem Phys; 2022 Feb; 24(8):5125-5137. PubMed ID: 35156677
[TBL] [Abstract][Full Text] [Related]
9. Discovery of
Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
[TBL] [Abstract][Full Text] [Related]
10. Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators.
Tsujikawa LM; Kharenko OA; Stotz SC; Rakai BD; Sarsons CD; Gilham D; Wasiak S; Fu L; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Biomed Pharmacother; 2022 Aug; 152():113230. PubMed ID: 35687908
[TBL] [Abstract][Full Text] [Related]
11. Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails.
Liu Y; Wang X; Zhang J; Huang H; Ding B; Wu J; Shi Y
Biochemistry; 2008 Jun; 47(24):6403-17. PubMed ID: 18500820
[TBL] [Abstract][Full Text] [Related]
12. FAM222A, Part of the BET-Regulated Basal Endothelial Transcriptome, Is a Novel Determinant of Endothelial Biology and Angiogenesis-Brief Report.
Tzani A; Haemmig S; Cheng HS; Pérez-Cremades D; Heuschkel MA; Jamaiyar A; Singh SA; Aikawa M; Yu PB; Wang T; Sun Y; Feinberg MW; Plutzky J
Arterioscler Thromb Vasc Biol; 2024 Jan; 44(1):143-155. PubMed ID: 37942611
[TBL] [Abstract][Full Text] [Related]
13. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4.
Wang Q; Li Y; Xu J; Wang Y; Shi D; Liu L; Leung EL; Yao X
Proteins; 2019 Jan; 87(1):3-11. PubMed ID: 30260047
[TBL] [Abstract][Full Text] [Related]
14. Bromodomain Interactions with Acetylated Histone 4 Peptides in the BRD4 Tandem Domain: Effects on Domain Dynamics and Internal Flexibility.
Wernersson S; Bobby R; Flavell L; Milbradt AG; Holdgate GA; Embrey KJ; Akke M
Biochemistry; 2022 Nov; 61(21):2303-2318. PubMed ID: 36215732
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Characterization of a Positron Emission Tomography Imaging Probe Selectively Targeting the Second Bromodomain of Bromodomain Protein BRD4.
Bai P; Lan Y; Wang H; Liu Y; Striar R; Yuan G; Afshar S; Zagaroli JS; Tocci DR; Langan AG; Wang C
Bioconjug Chem; 2021 Aug; 32(8):1711-1718. PubMed ID: 34139120
[TBL] [Abstract][Full Text] [Related]
16. A 7-methoxybicoumarin derivative selectively inhibits BRD4 BD2 for anti-melanoma therapy.
Yang GJ; Wang W; Lei PM; Leung CH; Ma DL
Int J Biol Macromol; 2020 Dec; 164():3204-3220. PubMed ID: 32860796
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections.
Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893
[TBL] [Abstract][Full Text] [Related]
18. A theoretical insight into selectivity of inhibitors toward two domains of bromodomain-containing protein 4 using molecular dynamics simulations.
Su J; Liu X; Zhang S; Yan F; Zhang Q; Chen J
Chem Biol Drug Des; 2018 Mar; 91(3):828-840. PubMed ID: 29139214
[TBL] [Abstract][Full Text] [Related]
19. TGF-β signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling.
Cooley BC; Nevado J; Mellad J; Yang D; St Hilaire C; Negro A; Fang F; Chen G; San H; Walts AD; Schwartzbeck RL; Taylor B; Lanzer JD; Wragg A; Elagha A; Beltran LE; Berry C; Feil R; Virmani R; Ladich E; Kovacic JC; Boehm M
Sci Transl Med; 2014 Mar; 6(227):227ra34. PubMed ID: 24622514
[TBL] [Abstract][Full Text] [Related]
20. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
